Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients

Increased Expression of P-Glycoprotein and Doxorubicin Chemoresistance of Metastatic Breast Cancer Is Regulated by miR-298

(2012) Lili Bao et al.   AMERICAN JOURNAL OF PATHOLOGY

Expression of human ABCB5 confers resistance to taxanes and anthracyclines

(2012) Takaaki Kawanobe et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Reduced miR-128 in Breast Tumor-Initiating Cells Induces Chemotherapeutic Resistance via Bmi-1 and ABCC5

(2011) Y. Zhu et al.   CLINICAL CANCER RESEARCH

Molecular Evolutionary Analysis of ABCB5: The Ancestral Gene Is a Full Transporter with Potentially Deleterious Single Nucleotide Polymorphisms

(2011) Karobi Moitra et al.   PLoS One

p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance

(2010) Ji Yeon Yang et al.   BMC CANCER

Pharmacogenetics of Target Genes Across Doxorubicin Disposition Pathway: A Review

(2010) Suman Lal et al.   CURRENT DRUG METABOLISM

Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer

(2009) M. Pajic et al.   CANCER RESEARCH

Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients

(2008) Suman Lal et al.   CANCER SCIENCE

PXR Pharmacogenetics: Association of Haplotypes with Hepatic CYP3A4 and ABCB1 Messenger RNA Expression and Doxorubicin Clearance in Asian Breast Cancer Patients

(2008) E. Sandanaraj et al.   CLINICAL CANCER RESEARCH

ABC multidrug transporters: structure, function and role in chemoresistance

(2007) Frances J Sharom   PHARMACOGENOMICS